Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks
ConditionMpox
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age5-80
SponsorUniversity of Birmingham
About this trial
The MPXV CARE study principally aims to use clinical and epidemiology data to target specific individuals willing and able to provide appropriate and proportionate biological samples to develop novel immune diagnostics that support models of disease burden and future vaccine utilisation.
Eligibility criteria
Qualifiers
Healthy males and females aged between ages 5-80 years, who are able and willing to provide informed consent and will comply with the study requirements.
Group 1 (suspected exposure cohort) only
Live within or adjacent to an epidemiologically identified region of Mpox transmission
Close contacts of those with microbiologically confirmed Mpox
Disqualifiers
Unwilling or unable to provide informed consent to take part
Unwilling or unable to comply with study procedures
History of any suspected or confirmed disorder of the immune system that, in the opinion of the investigators, might impair the results of the study
Have a bleeding disorder deemed significant by a member of the study team
Trial design
Treatments tested in this trial
- ELISA
- Lateral flow assay
Treatment groups
650 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Birmingham
Lead sponsor
Rwanda Biomedical Centre
Collaborator
Source ClinicalTrials.gov